A New Diagnosis at 28, and a Faster Clock No One Mentioned
Two different arguments point at the same aggressive answer for him — but they aren't the same argument, and which one the team actually relies on matters for the next patient whose age and A1c don't agree.
Devon K., a 28-year-old man, just started his first year teaching high school history, a job he describes as exhausting in a good way — long days grading papers, a schedule that hasn't left much room for the gym visits he used to keep up in college. A routine physical for his new teaching contract turned up a fasting glucose of 214 mg/dL, confirmed on repeat, with an A1c of 9.8% and no prior diagnosis of diabetes. He has no family history he's aware of, a BMI of 29, and reports no polyuria or polydipsia he'd specifically noticed, though in retrospect he says he's "been more tired than usual" for a few months.
His age and his A1c both point in the same direction, but for genuinely different reasons. Young-onset type 2 diabetes — diagnosed under 40 — has been shown in comparative studies, including the RISE consortium's own work, to carry a faster trajectory of beta-cell functional decline than older-onset disease, meaning the window to preserve remaining insulin- secreting capacity may close faster for him than it would for an older patient with the same A1c. Separately, and on its own terms, several current treatment guidelines already recommend starting combination therapy at diagnosis when A1c sits significantly above target, independent of age — a threshold his 9.8% clears without needing the age argument at all.
Two different reasons pointing at the same aggressive answer
I'd start with metformin alone and see how he responds before adding anything else. That's still the guideline-standard first step, it's the least costly and least complex option, and no trial measuring actual clinical outcomes — not just beta-cell function surrogates — has yet shown early combination therapy is worth the added burden as routine practice.
I'd start combination therapy today, specifically because he's young-onset. The RISE consortium's comparative data found young-onset patients losing beta-cell function faster than older-onset patients with similar presenting glucose — which means the window where early treatment can actually preserve his remaining capacity may close faster than the stepwise approach was designed around.
I take the point about hard-outcome trials fairly — we don't have one specifically proving this saves him a harder outcome years from now. But waiting for that trial while his beta-cell reserve keeps declining is itself a real choice, not a neutral one.
I'd get to the same practical answer through a narrower argument. Several current guidelines already recommend starting dual therapy at diagnosis when A1c sits significantly above target — his 9.8% clears that threshold on its own, without needing the young-onset beta-cell argument to justify it.
I'd rather anchor today's decision to an established, numeric guideline criterion than to an age-based heuristic that isn't yet formally adopted, even though in his case both arguments land on the same recommendation. It matters for how we'd counsel a different patient later where the two factors don't point the same way.
Metformin and a GLP-1 receptor agonist started together, with a follow-up A1c planned at three months. All three voices agreed on the practical regimen, though they documented their reasoning separately — the primary care physician noted this was justified specifically by the A1c threshold, not as a general endorsement of early combination therapy for every new diagnosis.
Not agreed: whether his C-peptide should be rechecked in a year to see whether early combination therapy measurably slowed his beta-cell decline relative to expected trajectory. The endocrinologist wanted this tracked as a real data point; the primary care physician saw it as research-oriented monitoring beyond what routine care requires. Left open for the endocrinology follow-up to decide.